1 |
Kim HJ, Park JM, Cha JG, et al. -FDG PET/CT in the clinical assessment of patients with multiple myeloma: a pilot study. Korean J Med 2012;82:689-695.
DOI
|
2 |
D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007;137:49-63.
DOI
|
3 |
Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005;184:1199-1204.
DOI
ScienceOn
|
4 |
Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-1463.
|
5 |
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: multiple myeloma [Internet]. National Comprehensive Cancer Network, c2011 [cited 2011, 26th July]. Available from: http://www. nccn.org/professionals/physician_gls/pdf/ myeloma.pdf.
|
6 |
Haznedar R, Akı SZ, Akdemir OU, et al. Value of 18Ffluorodeoxyglucose uptake in positron emission tomography/ computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 2011;38:1046-1053.
DOI
ScienceOn
|
7 |
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011;118:5989-5995.
DOI
ScienceOn
|